Conversely, in the last update of NCCN guidelines (162), the genomic testing, including tumor mutational burden or RET somatic genotyping was suggested in case of symptomatic, progressive, metastatic disease, according to RECIST, in patients who are germline wild-type or germline unknown, before starting treatment with highly selective RET inhibitors. Here, RET is linked to metastatic neoplasm.